Magenta Therapeutics, Inc.
NASDAQ: MGTA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen F. Mahoney MBA
- Employees
- 67
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Market cap
- $42.4M
- Website
- https://www.magentatx.com
Loading MGTA…
Loading profile data…Frequently asked questions about MGTA
What does Magenta Therapeutics, Inc. (MGTA) do?
Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 ant...
Where does MGTA trade?
Magenta Therapeutics, Inc. (MGTA) trades on the NASDAQ Global Market.
What sector is MGTA in?
Magenta Therapeutics, Inc. (MGTA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Magenta Therapeutics, Inc.?
Stephen F. Mahoney MBA is the chief executive officer of Magenta Therapeutics, Inc. (MGTA).
Where is Magenta Therapeutics, Inc. headquartered?
Magenta Therapeutics, Inc. is headquartered in United States.
Does MGTA pay a dividend?
Magenta Therapeutics, Inc. (MGTA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MGTA go public?
Magenta Therapeutics, Inc. (MGTA) completed its initial public offering in 2018.